Home › Mutual Funds › Nippon Mutual Fund › Nippon India Pharma Fund - Growth
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Growth

Add To Compare

previously known as Reliance Pharma Gr until

556.107 (-0.221%)
NAV on July 24, 2026
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 9,044 cr
Turnover Ratio 14.27%
Expense Ratio 1.52%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: 0.77%
  • 1Y: 5.29%
  • 3M: 9.68%
  • 3Y: 18.87%
  • 6M: 14.42%
  • 5Y: 12.15%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 21 years) Kinjal Desai (Since about 8 years) Amber Singhania (Since 5 months)
ISIN INF204K01968
Fund Family Nippon
P/E Ratio 38.20
P/B Ratio 5.65
Launch Date June 05, 2004
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -1.68
Beta 0.89
R-Squared 94.72
Info Ratio -1.04
Tracking Err 3.95
Sortino 1.535
Sharpe 0.908
Std Dev 15.221
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet
-


Other plans of Nippon India Pharma


Other Equity funds by Nippon

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon Fund